Skip to content
  • Home
  • Journalists
    • Headlines
  • Community
    • Businesses
    • Jobs
    • Learning
    • Marketplace
  • Store
(@)

How a Drug Company Made $114 Billion by Gaming the U.S. Patent System

AbbVie for years delayed competition for its blockbuster drug Humira, at the expense of patients and taxpayers. The monopoly is about to end.

Rebecca Robbins
Author: Rebecca Robbins

Written by

Rebecca Robbins

in

Antitrust Laws and Competition Issues, Drugs (Pharmaceuticals), Humira (Drug), Intellectual Property, Inventions and Patents, Prices (Fares, Fees and Rates), Suits and Litigation (Civil)
←When Private Equity Came for the Toddler Gyms
How a Football Superfan in a Wolf Costume Ended Up in a Cage→

More posts

  • Protesters, leaders push back against DHS over Newark detention facility conditions

  • Goldman and Lander spar hard over Israel

  • Snowflake climbs after Q1 results top expectations, guidance gets a boost

  • Synopsys drops despite better than expected Q2 results, big boost to full-year guidance

About Us


Support Us

Trademark & Copyright 1998 – 2025 · MOSAEC

  • Facebook
  • Instagram
  • LinkedIn
  • YouTube